Replimune Group, Inc. (REPL)
NASDAQ: REPL · Real-Time Price · USD
9.95
-0.23 (-2.26%)
At close: Dec 15, 2025, 4:00 PM EST
9.95
0.00 (0.00%)
Pre-market: Dec 16, 2025, 4:20 AM EST
Replimune Group Employees
Replimune Group had 479 employees as of March 31, 2025. The number of employees increased by 148 or 44.71% compared to the previous year.
Employees
479
Change (1Y)
148
Growth (1Y)
44.71%
Revenue / Employee
n/a
Profits / Employee
-$647,731
Market Cap
780.51M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 479 | 148 | 44.71% |
| Mar 31, 2024 | 331 | 47 | 16.55% |
| Mar 31, 2023 | 284 | 78 | 37.86% |
| Mar 31, 2022 | 206 | 54 | 35.53% |
| Mar 31, 2021 | 152 | 30 | 24.59% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
REPL News
- 19 days ago - The Short List — Top 10 Most Shorted Stocks Right Now - Benzinga
- 5 weeks ago - Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025) - GlobeNewsWire
- 5 weeks ago - Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Why Replimune Stock Was Soaring Today - The Motley Fool
- 2 months ago - Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma - GlobeNewsWire
- 2 months ago - Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025 - GlobeNewsWire
- 3 months ago - SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - GlobeNewsWire
- 3 months ago - Why Replimune Stock Was Tumbling Again Today - The Motley Fool